ES2180799T3 - Tetrahidroquinolinas como antagonistas de nmda (n-metil-d-aspartato). - Google Patents

Tetrahidroquinolinas como antagonistas de nmda (n-metil-d-aspartato).

Info

Publication number
ES2180799T3
ES2180799T3 ES96933399T ES96933399T ES2180799T3 ES 2180799 T3 ES2180799 T3 ES 2180799T3 ES 96933399 T ES96933399 T ES 96933399T ES 96933399 T ES96933399 T ES 96933399T ES 2180799 T3 ES2180799 T3 ES 2180799T3
Authority
ES
Spain
Prior art keywords
antagonists
tetrahydrochinolines
nmda
aspartate
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96933399T
Other languages
English (en)
Inventor
Fabio Romano Di
Simone Giacobbe
Barbara Bertani
Fabrizio Micheli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline SpA
Original Assignee
GlaxoSmithKline SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9519893.3A external-priority patent/GB9519893D0/en
Priority claimed from GBGB9617306.7A external-priority patent/GB9617306D0/en
Application filed by GlaxoSmithKline SpA filed Critical GlaxoSmithKline SpA
Application granted granted Critical
Publication of ES2180799T3 publication Critical patent/ES2180799T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE DESCRIBEN COMPUESTOS DE FORMULA (I) O UNA SAL, O UN ESTER METABOLICAMENTE LABIL DE ESTOS, PROCEDIMIENTOS PARA SU PREPARACION Y SU USO COMO ANTAGONISTAS DE AMINOACIDOS DE EXCITACION.
ES96933399T 1995-09-29 1996-09-26 Tetrahidroquinolinas como antagonistas de nmda (n-metil-d-aspartato). Expired - Lifetime ES2180799T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9519893.3A GB9519893D0 (en) 1995-09-29 1995-09-29 Heterocyclic compounds
GBGB9617306.7A GB9617306D0 (en) 1996-08-17 1996-08-17 Heterocyclic compounds

Publications (1)

Publication Number Publication Date
ES2180799T3 true ES2180799T3 (es) 2003-02-16

Family

ID=26307841

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96933399T Expired - Lifetime ES2180799T3 (es) 1995-09-29 1996-09-26 Tetrahidroquinolinas como antagonistas de nmda (n-metil-d-aspartato).

Country Status (29)

Country Link
US (1) US5977136A (es)
EP (1) EP0854867B1 (es)
JP (1) JP4108123B2 (es)
KR (1) KR100464895B1 (es)
CN (1) CN1130346C (es)
AP (1) AP876A (es)
AR (1) AR005233A1 (es)
AT (1) ATE221520T1 (es)
AU (1) AU708148B2 (es)
BR (1) BR9610733A (es)
CA (1) CA2232509A1 (es)
CZ (1) CZ292379B6 (es)
DE (1) DE69622731T2 (es)
DK (1) DK0854867T3 (es)
EA (1) EA000875B1 (es)
ES (1) ES2180799T3 (es)
HK (1) HK1009133A1 (es)
HU (1) HUP9900040A3 (es)
IL (1) IL123322A0 (es)
IS (1) IS4677A (es)
MX (1) MX9801967A (es)
NO (1) NO310355B1 (es)
NZ (1) NZ319596A (es)
PL (1) PL186781B1 (es)
PT (1) PT854867E (es)
SI (1) SI0854867T1 (es)
TR (1) TR199800531T1 (es)
TW (1) TW460465B (es)
WO (1) WO1997012870A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9617305D0 (en) * 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds
GB9706294D0 (en) * 1997-03-26 1997-05-14 Glaxo Wellcome Spa Heterocyclic compound
MY125037A (en) 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives
TW555757B (en) * 1998-07-31 2003-10-01 Akzo Nobel Nv Aminomethylcarboxylic acid derivatives
WO2000008018A1 (fr) * 1998-08-07 2000-02-17 Takeda Chemical Industries, Ltd. Derives de benzothiepine, leur procede de preparation et leurs utilisations
GB9929037D0 (en) * 1999-12-08 2000-02-02 Glaxo Wellcome Spa Heterocyclic derivatives
CA2470578C (en) * 2001-12-28 2010-10-12 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
DE10236910A1 (de) * 2002-08-12 2004-03-11 Grünenthal GmbH Substituierte 1,2,3,4-Tetrahydrochinolinderivate
US7910751B2 (en) * 2005-07-22 2011-03-22 Mochida Pharmaceutical Co., Ltd. Heterocyclidene acetamide derivative
RU2451014C2 (ru) * 2005-07-22 2012-05-20 Мотида Фармасьютикал Ко., Лтд. Новое производное гетероциклиден ацетамида
PL2268644T3 (pl) 2008-03-05 2012-01-31 Boehringer Ingelheim Int Tricykliczne pochodne piperydyny, leki zawierające te związki, ich zastosowanie i sposoby ich wytwarzania
EP2286808A1 (en) * 2009-08-18 2011-02-23 Rheinische Friedrich-Wilhelms Universität Cytohesin inhibitors
WO2011101774A1 (en) 2010-02-16 2011-08-25 Pfizer Inc. (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors
SG183321A1 (en) 2010-02-19 2012-09-27 Boehringer Ingelheim Int Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
EP2760868B1 (en) 2011-08-17 2018-04-25 Boehringer Ingelheim International GmbH Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation
WO2016114655A1 (en) * 2015-01-12 2016-07-21 Ry Pharma B.V. Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation
WO2017065602A1 (en) * 2015-10-13 2017-04-20 Ry Pharma B.V. Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0386839B1 (en) * 1989-03-08 1997-01-15 Merck Sharp & Dohme Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders

Also Published As

Publication number Publication date
PT854867E (pt) 2002-12-31
HK1009133A1 (en) 1999-05-28
IS4677A (is) 1998-02-27
TR199800531T1 (xx) 1998-06-22
JP4108123B2 (ja) 2008-06-25
DE69622731T2 (de) 2003-02-20
NO981396D0 (no) 1998-03-27
NO981396L (no) 1998-05-27
AU7214896A (en) 1997-04-28
AU708148B2 (en) 1999-07-29
CN1202887A (zh) 1998-12-23
HUP9900040A3 (en) 2001-01-29
SI0854867T1 (en) 2003-02-28
US5977136A (en) 1999-11-02
JPH11512728A (ja) 1999-11-02
IL123322A0 (en) 1998-09-24
KR19990063850A (ko) 1999-07-26
WO1997012870A1 (en) 1997-04-10
CA2232509A1 (en) 1997-04-10
PL325966A1 (en) 1998-08-17
CZ94098A3 (cs) 1998-07-15
NZ319596A (en) 1999-09-29
DK0854867T3 (da) 2002-12-02
EA000875B1 (ru) 2000-06-26
TW460465B (en) 2001-10-21
AP9801212A0 (en) 1998-03-31
KR100464895B1 (ko) 2005-05-16
PL186781B1 (pl) 2004-02-27
DE69622731D1 (de) 2002-09-05
EA199800230A1 (ru) 1998-10-29
AR005233A1 (es) 1999-04-28
CN1130346C (zh) 2003-12-10
EP0854867B1 (en) 2002-07-31
EP0854867A1 (en) 1998-07-29
HUP9900040A2 (hu) 1999-04-28
AP876A (en) 2000-09-27
MX9801967A (es) 1998-08-30
BR9610733A (pt) 1999-07-13
ATE221520T1 (de) 2002-08-15
NO310355B1 (no) 2001-06-25
CZ292379B6 (cs) 2003-09-17

Similar Documents

Publication Publication Date Title
ES2180799T3 (es) Tetrahidroquinolinas como antagonistas de nmda (n-metil-d-aspartato).
CY1112274T1 (el) Νεοι ολιγοσακχαριτες, η παρασκευh τους και οι φαρμακευτικες συνθεσεις οι οποιες τους περιεχουν
ATE297203T1 (de) Antithrombotische mitteln
AR077414A2 (es) Compuestos de piperazina como antagonistas de taquinina sus sales y solvatos composiciones farmaceuticas que lo contienen su uso y procesos para su preparacion
EA200200628A1 (ru) Новые производные 1,3-дигидро-2н-индол-2-она и их применение в качестве лигандов рецепторов аргинин-вазопрессина v1b и v1a
RU93055882A (ru) Производные n-сульфонил-2-оксоиндола, способ их получения, исходные для их получения, фармацевтическая композиция на их основе
AR012673A1 (es) Compuesto de ester de etilenglicol de monohidrobenzoporfirina utiles para terapia fotodinamica, composiciones farmaceuticas y uso de los mismos.
HUP0000564A2 (hu) Olajos szuszpenzió alakú gyógyászati készítmények
ES2176456T3 (es) Procedimiento de preparacion de un compuesto inhibidor del vih proteasa.
ES2137549T3 (es) Derivados antifungicos de sordaridina.
MY118828A (en) Substituted amino compounds and their use as substances having an analgesic effect
MX9706605A (es) Derivados de indol como antagonistas de los aminoacidos exitadores.
ES2088011T3 (es) Antagonistas de aminoacidos excitadores.
ES2180737T3 (es) Conjugado para la dosificacion individual de medicamentos, su procedimiento de preparacion y su uso en los mismos.
ES2109509T3 (es) Procedimiento para la preparacion de beta-fenilisoserina y de sus analogos.
BR9507381A (pt) Composto uso de um composto processo para o tratamento de um manifero composição famacèutica e processo para a preparação de compostos
BR9814495A (pt) Composto, processo para prepará-lo, uso do mesmo, composição farmacêutica, e, processo
AR031126A1 (es) Acidos amino(oxo)aceticos inhibidores de la proteina tirosina fosfatasa
ES2052850T3 (es) Un procedimiento para preparar un compuesto de hidrazona.
AR247327A1 (es) Una composicion herbicida
DE69330601D1 (de) Serotoninergische ergolin derivate
MX9303605A (es) Derivados de azabicicloheptano n-substituidas, su obtencion y uso.
UY26144A1 (es) Nuevas formas cristalinas de un antibiótico macrolido.
DE69710574D1 (de) Diclofenac/gamma-cyclodextrin klathrat komponente
EA200000112A1 (ru) Новая композиция